Tuesday, 23 February 2021 13:29

Prati-Donaduzzi to make treatment with Brazilian Cannabidiol more accessible

Canabidiol Prati-Donaduzzi. Foto Aparecido da Silva.jpg

The new concentrations of Cannabidiol Prati-Donaduzzi bring even more access to treatment for the population. Photo: Aparecido da Silva.

The first pharmaceutical industry to obtain authorization from the National Health Regulatory Agency (Anvisa) to commercialize Brazilian Cannabidiol will allow even more access to treatment for the population in the coming days. Prati-Donaduzzi awaits publication by Anvisa for the launch of two new concentrations of the product on the market, 20 mg/ml and 50 mg/ml, enabling new dosage options and prices for the only 100% national Cannabidiol, with proven quality and effectiveness.

The company has been selling Cannabidiol Prati-Donaduzzi since April last year, in a concentration of 200mg/ml. According to the CEO of the pharmaceutical company, Eder Fernando Maffissoni, the forecast is that the 20 mg/ml product will reach the consumer in the range of R$ 240.00 to R$ 280.00 (Brazilian currency).

“We are happy to offer more possibilities for treatment with Cannabidiol for patients. Our products meet all the quality standards of a pharmaceutical industry. We are a benchmark in the production of medicines in the country and we are committed to the health of Brazilians”, ensures Maffissoni.


Currently, Cannabidiol Prati-Donaduzzi at a concentration of 200 mg/ml contains 6,000 mg of Cannabidiol per 30 ml bottle. The new presentations offer a solution for those seeking treatment in lower concentrations for different pathologies and cheaper options. The new products will be available in oral solution, in the presentation of 30 ml, which means that in the concentration of 50 mg ml there will be 1,500 mg of cannabidiol per bottle and the 20 mg will contain 600 mg.

 “The difference between the products is only the concentration of cannabidiol per ml, so they are also produced from pure active principle and totally free of the psychoactive substance THC (Tetrahydrocannabinol), which, together with the constant national availability, are the main differentials of our products”, he emphasizes.

All concentrations of Cannabidiol Prati-Donaduzzi are versions of the drug that is in the final stage of a Phase III clinical study, through a public-private partnership between Prati-Donaduzzi and Ribeirão Preto School of Medicine (FMRP) of the University of São Paulo.

After making the treatment with Brazilian cannabidiol a reality, the pharmaceutical company bets on the new concentrations to extend the treatment to patients who find in the products the improvement in the quality of life, evidencing its social commitment to the population. “Prati-Donaduzzi's new steps contribute to the accessibility of treatment in the country and reinforce the strong benchmark of the pharmaceutical company in cannabidiol”, concludes Maffissoni.


Read 113 times